Open Access Full Text Article

ORIGINAL RESEARCH

Prognostic factors in pediatric pneumococcal meningitis patients in mainland China: a retrospective multicenter study

This article was published in the following Dove Press journal: Infection and Drug Resistance

Caiyun Wang,¹ Hongmei Xu,² Jikui Deng,³ Hui Yu,⁴ Yiping Chen,⁵ Shifu Wang,⁶ Weichun Huang,⁷ Jianhua Hao,⁸ Chun Wang,⁹ Huiling Deng,¹⁰ Yinghu Chen¹

¹Infection Disease Department, The Children's Hospital of Zhejiang University School of Medicine, Hangzhou, 310052, People's Republic of China; ²Infection Disease Department, Children's Hospital of Chongqing Medical University, Chongqing 400014, People's Republic of China; ³Department of Infectious Diseases, Shenzhen Children's Hospital, Shenzhen 518038, People's Republic of China; ⁴Department of Infectious Diseases, Children's Hospital of Fudan University, Shanghai 201102, People's Republic of China; ⁵Infection Disease Department, Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, People's Republic of China; ⁶Department of Children's Medical Laboratory Diagnosis Center, Qilu Children's Hospital of Shandong University, Jinan, 250022, People's Republic of China; ⁷Department of Clinical Laboratory, Shanghai Children's Medical Center of Shanghai Jiaotong University School of Medicine, Shanghai, 200127, People's Republic of China; ⁸Infection Disease Department, Kaifeng Children's Hospital, Kaifeng 475000, People's Republic of China; ⁹Clinical Laboratory, Children's Hospital of Shanghai Jiaotong University School of Medicine, Shanghai, 200040, People's Republic of China; ¹⁰Department of Infectious Diseases, Xi'an Children's Hospital, Xi'an, 710003, People's Republic of China

Correspondence: Yinghu Chen Department of Infection Disease, the Children's Hospital of Zhejiang University School of Medicine, No. 3333, Binsheng Road, Binjiang District, Hangzhou, Zhejiang 310052, People's Republic of China Tel +861 385 715 4891 Email cyh18@zju.edu.cn



Background: Prognosis of pneumococcal meningitis (PM) remains very poor, especially in less developed countries. Currently, few multi-centric studies on pediatric PM have been reported in mainland China.

Objectives: This study aimed to explore the correlation of clinical and laboratory findings with complications and prognosis in pediatric PM.

Methods: The pediatric PM patients were retrospectively recruited from ten pediatric tertiary hospitals across China between January 2013 and June 2018. Clinical, biochemical, and microbiological data and follow-up information were collected. Predictive factors for complications and prognostic factors for overall survival (OS) and sequelae-free survival (SFS) were analyzed.

Results: A total of 132 pediatric PM patients were included. Seventy-one patients had complications, 25 patients died, and 39 patients had neurological sequelae. Multivariate logistic regression suggested that age less than 28 months (adjusted OR=2.654, 95% CI=1.067-6.600, P=0.036) and lower white blood cells in blood (aOR=3.169, 95% CI=1.395-7.202, P=0.006) were associated with high risk of complications. Multivariate Cox's proportional hazard regression suggested that age less than 28 months (aHR=6.479, 95%CI=1.153-36.404, P=0.034), coma (aHR=9.808, 95%CI=2.802-34.323, P=0.000), and non-adjuvant steroid therapy (aHR=4.768 95%CI=1.946-11.678, P=0.001) were independent prognostic factors for poor OS; coma (aHR=5.841, 95%CI=2.652-12.864, P=0.000), septic shock on admission (aHR=2.949, 95%CI=1.049-8.290, P=0.040), and lower glucose level in cerebrospinal fluid (CSF) (aHR=2.523, 95%CI=1.336-4.765, P=0.004) were independent prognostic factors for poor SFS.

Conclusion: Age, coma, and adjuvant steroid therapy were independent factors for OS, while coma, septic shock on admission, and lower glucose level in CSF were independent factors for SFS in pediatric PM patients. These factors might be used to identify PM patients with poor prognosis and guide individual treatment.

Keywords: pneumococcal meningitis, clinical findings, complication, prognosis, pediatric

Introduction

Streptococcus pneumoniae is a common cause of meningitis and pneumococcal meningitis (PM) accounts for 50% of bacterial meningitis globally.^{1,2} PM is also a common bacterial meningitis in China.³ Most PM patients present with a headache, neck stiffness, and fever.⁴ Culture of cerebrospinal fluid (CSF) obtained from a lumbar puncture should be performed to confirm the diagnosis of PM.

Infection and Drug Resistance 2019:12 1501-1512

© 2019 Wang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission form Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please esp aragraphs 4.2 and 5 of our Terms (http://www.dovepress.com/terms.php). In spite of progress in diagnosis, antibiotic therapy strategies, and intensive care, PM is associated with a mortality rate of 6%–17% in high-income countries including US and some European countries.^{5–8} However, in developing countries and regions such as sub-Saharan Africa, the mortality of PM patients has been reported to be as high as 73%.^{7,9–13} Among surviving patients, 25%–63% suffer from long-term neurological sequelae,^{5,9,14,15} which significantly affect the quality of life of survivors.

Early identification of patients with poor prognosis contributes to individualized treatment and more aggressive therapeutic strategies. A series of clinical features, biochemical, and microbiological factors have been identified as prognostic factors in PM. The most important prognostic factors associated with mortality of PM patients include C-reactive protein,⁵ age,^{16,17} score on SOFA, Glasgow Score, severe hypoglycorrhachia,¹⁷ corticosteroid treatment,¹⁸ and glucose in CSF.¹⁹ And the most important prognostic factors in relation to neurological handicaps seem to be hypoglycorrhachia,^{20–24} shock, coma and convulsions on admission or during hospitalization,²⁵ mechanical ventilation requirement, late diagnosis, ataxia, and steroid treatment.²⁶

However, these studies are mainly performed in European and American countries and limited to a few research centers. Further multicenter research is required to verify the prognostic value of these factors and improve clinical management of PM patients in mainland China. The present study aimed to recruit pediatric PM patients retrospectively from multiple hospitals in mainland China and investigate the risk factors of complications as well as the prognostic factors of overall survival (OS) and neurological sequelae-free survival (SFS) in pediatric PM patients.

Methods

Participants

A multicenter retrospective study was performed to consecutively recruit pediatric PM patients between January 2013 to June 2018 from ten pediatric tertiary hospitals in eight regions in mainland China (Shanghai, Hangzhou, Wenzhou, Xi'an, Chongqing, Shenzhen, Shandong, and Kaifeng).

Patient inclusion and exclusion criteria

Inclusion criteria: 1) age less than 5 years; 2) compatible with PM diagnosis criteria. Exclusion criteria: 1) patients

with known primary immunodeficiency (including humoral immunity disorders, T-cell and B-cell disorders, phagocytic disorders, and complement disorders) or known secondary immunodeficiency (including human immunodeficiency virus infection, nephrotic syndrome, diabetes, etc); 2) patients had no cranial computed tomography (CT) and magnetic resonance imaging (MRI) results. The diagnostic criteria of PM were as follows: 1) clinical signs and symptoms (bulging fontanelles, stiff or painful neck, vomiting, headache, persistent or recurrent fever, change in mental state, seizures, or focal neurologic signs) that comply with meningitis; 2) the results of CSF examination were abnormal (the white blood cell [WBC] count in CSF was more than 10×10^6 / L, in which the neutrophil should be dominant, or the glucose level in CSF was less than 2.78 mmol/L, or the protein level in CSF was more than 0.45 g/L; 3) positive blood culture for S. pneumoniae with positive DNA testing of S. pneumoniae in CSF, or positive CSF culture for S. pneumoniae.

Identification of S. pneumoniae isolates

S. pneumoniae isolate was identified by automatic bacterial identification system (VITEK Compact, France) or Optochin Discs (OXOID, UK) according to the National Guide to Clinical Laboratory Procedures.

Data collection

Case record forms were used to collect data of patients' history, symptoms and signs, laboratory and microbiological findings, clinical course, complications in hospital, vaccination status, treatment, clinical outcome, neurological deficits at discharge, and follow-up visits from the ten hospitals listed in the affiliations. Underlying predisposing factors, including asplenia, history of head trauma or neurosurgery in the past 3 months, anatomical or infectious otorhinolaryngologic disorders. and immunocompromised status, were recorded. Patients with an altered immune status owing to the use of immunosuppressive drugs or splenectomy, diabetes mellitus were considered immunocompromised. Consciousness of the patients was accessed by Glasgow Coma Scale and grouped into normal, decline in consciousness, and coma.

Follow-up

PM patients were followed-up every month in the first year, and every 6 months thereafter. The last

follow-up date was September 30, 2018. OS was calculated from the onset date to the time of death of any cause while SFS was calculated from the onset date to the time of neurological deficits or death of any cause. Assessment was performed by a senior, experienced physician. We called the families to come to hospital for a follow-up visit to complete pediatric exam with a potential neuropsychological assessment. A telephonebased interview was suggested to the families who could not come to hospital. Physical examination, Gesell Development Scale test (<3 years and 10 months), Wechsler Intelligence Scale test (≥ 3 years and 10 months), and Behavior Questionnaire test (≥ 2 years) were performed. Neurological sequela was evaluated according to the patients' last results of brain MRI, brainstem auditory evoked potential (BAEP), auditory brainstem response, and visual acuity. Neurological deficits included seizures, hemiparesis, ataxia, hydrocephalus and subdural hydrops or empyema, psychomotor retardation, hearing impairment, and visual impairment. Psychomotor retardation was indicated if gross-motor functions (neck control, sitting, walking, running, etc), fine-motor functions (reaching, grasping, drawing, etc), and activities of daily living (toileting, dressing, eating, writing, etc) were affected. Hearing was considered as impaired when the better ear failed to detect a threshold

of 40 dB. Visual impairment was noted if the routine ophthalmic examination results of vision, visual field, fundus oculi, and eye movement were abnormal.

Statistics

Statistical analysis was performed using SPSS 19.0 software (IBM Corporation, Armonk, NY, USA) and GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA). Data were presented as count (%), or median (interquartile range [IQR]). X-title software was used to obtain the best optimal cut-off values of the continuous variables based on prognosis. Chi-squared test and logistic regression analysis were used to investigate the associations of clinical characteristics and laboratory parameters with complications. Kaplan-Meier curves with logrank test and Cox's proportional hazard regression were applied to assess the associations of clinical charactery parameters with prognosis. *P*-value <0.05 was considered significant.

Results

Baseline clinical characteristics

Data from one hundred and sixty-one pediatric patients diagnosed with PM were collected from ten pediatric



Figure I Flowchart of pediatric pneumococcal meningitis (PM) patients' inclusion.

Characteristic	Cases n (%)	Characteristic	Cases n (%)
Total Sex Male Female Age Median age (IQR, months) ≤28 months	132(100) 88(66.7) 44(33.3) 13(28) 94(71.2)	Neurological findings on admission Triad syndrome Abnormal mental status Coma Convulsions on admission Laboratory findings	22(16.7) 46(34.8) 20(15.2) 49(37.1)
>28 months Hospital stay Median time (IQR, days)	38(28.8) 22(18)	Positive CSF culture Positive blood culture Positive CSF and blood culture	76(57.6) 31(23.5) 25(18.9)
Symptoms and signs on admission Headache Nausea Neck stiffness Bulging fontanelles Fever Septic shock	33(25.0) 80(60.6) 68(51.5) 27(20.5) 129(97.7) 7(5.3)	WBCs in blood (median, IQR, ×10 ⁹ /L) Neutrophil proportion in blood (median, IQR, %) C-Reactive Protein (median, IQR, mg/L) WBCs in CSF (median, IQR, ×10 ⁶ /L) Neutrophil proportion in CSF (median, IQR, %) Protein in CSF (median, IQR, g/L) Glucose in CSF (median, IQR, mmol/L)	14.5(14.7) 78.5(17.5) 95.8(111.1) 400.0(1756.0) 80.0(12.8) 1.4 (2.6) 1.1 (1.9)
Mechanical ventilation Multiple organ failure Respiratory failure	17(11.4) 5(3.8) 9(6.8)	Focal neurological deficits n=107 Hypophrenia or behavioral deficits Aphasia	39(29.5) 18(13.6) 17(12.9)
Predisposing factors^a n=34 Recent or remote cerebral trauma CSF leakage Previous history of meningitis Intracranial structure malformation Previous intracranial surgery ^b Craniotomy	34(25.8) 11(8.3) 13(9.8) 6(4.5) 5(3.8) 4(3.0) 4(3.0)	Dyskinesia Hearing impairment Hydrocephalus Hemiparesis Cranial nerve palsies Secondary epilepsy Quadriplegia Subdural effusion or abscess	13(9.8) 12(9.1) 8(6.1) 8(6.1) 5(3.8) 4(3.0) 3(2.3) 2(1.5)
Concomitant diseases n=84 Pneumonia Sinusitis Mastoiditis Otitis Ear or intracranial abnormalities	84(63.6) 49(37.1) 22(16.7) 24(18.2) 5(3.8) 8(6.1)	Visual impairment Cerebellar ataxia Hypothalamus ataxia	2(1.5) 1(0.8) 1(0.8)

Notes: ^aPredisposing diseases were defined as previous head trauma, history of intracranial surgery, dura disruption, ear or intracranial abnormalities etc. ^bIntracranial surgery (ventriculostomy, cochlear implantation, ventriculoperitoneal shunt, removal of lateral ventricular reservoir sac, cranioplasty, etc.) Abbreviations: PM, pneumococcal meningitis; IQR, interquartile range; CSF, cerebrospinal fluid; WBC, white blood cell.

tertiary hospitals across China. Twenty-nine patients were excluded due to primary or secondary immunodeficiency, or age more than 5 years and 132 patients were finally included (Figure 1). As shown in Table 1, of the 132 patients, 88 were male and 44 were female. The median age of the patients was 13 months. Lumbar puncture was performed in all patients. Seventy-sixcases had a positive CSF culture for *S. pneumoniae*, 31 cases had a positive blood culture for *S. pneumoniae* with a positive DNA testing of S. pneumoniae in CSF, and 25 cases had both positive CSF culture and positive blood culture for S. pneumoniae. All patients had signs of meningitis.

An amount of 25.8% (34/132) of patients had predisposing factors for PM including cerebral trauma in eleven (8.3%), CSF leakage in 13 (9.8%), history of meningitis (ie, the patient had meningitis previously) in six (4.5%), intracranial structure malformation in five (3.8%), history of intracranial surgery in four (3.0%), and craniotomy in four (3.0%) (Table 1). Eighty-four PM patients were combined with other concomitant diseases including pneumoniae, mastoiditis, sinusitis, otitis, and ear or intracranial abnormalities. Fever and vomiting were the most frequent symptoms and signs on admission (97.7% and 60.6%, respectively). The consciousness status was altered in 46 patients on admission, of which 20 (15.2%) were in a coma.

Laboratory examination results were collected from medical records before or at admission. The medians of WBC counts, protein level in CSF, and glucose level in CSF were 14.5×10^{9} /L (IQR: 14.7×10^{9} /L), 1.4 g/L (IQR: 2.6 g/L), and 1.1 mmol/L (IQR: 1.9 mmol/L), respectively.

Complications and follow-up

PM complications were found in 53.8% (71/132) of patients by cranial CT and MRI (Table 2). Subdural effusion, sinusitis or otitis, cerebritis, cerebral edema, hydrocephalus, intracranial hemorrhage, and empyema or abscess were the most common abnormalities and present in 47 (35.6%), 35 (26.5%), 29 (22.0%), 22 (16.7%), 17 (12.9%), 15 (11.4%), and 12 (9.1%) patients, respectively. Forty-one patients were associated with more than one abnormality. Twenty-five patients (18.9%) died – all during hospitalization. Nine died

Table 2 Complications of 132 pediatric pneumococcal meningi-tis patients on admission and during hospitalization examined bycranial computed tomography (CT) or magnetic resonance ima-ging (MRI) for

Characteristic	Patients n (%) ^a
Total number of abnormalities ^b	71(53.8)
Subdural effusion	47(35.6)
Sinusitis or otitis	35(26.5)
Cerebritis	29(22.0)
Cerebral edema	22(16.7)
Hydrocephalus	17(12.9)
Intracranial hemorrhage	15(11.4)
Empyema or abscess	12(9.1)
Cerebral atrophy	7(5.3)
Skull fracture	7(5.3)
Cerebral hernia	5(3.8)
Brain infarction	4(3.0)
Arachnoid cyst	3(2.3)
Other abnormalities ^c	7(5.3)

Notes: ^aData are numbers (%). Percentages are calculated per number of episodes with cranial CT or MRI undertaken. ^bNumbers do not add up to totals because of the presence of multiple abnormalities in several patients. ^cMiddle ear malformation in three, pneumocephalus in two, meningioma in one, and cerebral vascular malformation in one.

within 1 week and 16 patients died 1–4 weeks after admission. The predefined neurological sequelae were evaluated in the 107 survivors during follow-up and identified in 39 patients. Hypophrenia or behavioral deficits, aphasia, dyskinesia, hearing impairment, and hydrocephalus were common focal neurological sequelae and present in 18 (13.6%), 17 (12.9%), 13 (9.8%), 12 (9.1%), and 8 (6.1%) patients of the 107 survivors, respectively (Table 1).

Associations of clinical findings and laboratory parameters with complications

Chi-squared test was used to investigate the associations of clinical findings and laboratory parameters with complications and the results suggested that age less than 28 months, visual impairment, convulsions on admission, lower WBCs in blood, and predisposing factors were associated with complications in pediatric PM patients (Table 3). Further multivariate logistic regression analysis revealed that age less than 28 months (aOR=2.654, 95% CI=1.067–6.600, P=0.036) and lower WBCs in blood (aOR=3.169, 95%CI=1.395–7.202, P=0.006) were independent predictive factors for complications in pediatric PM patients (Table 4).

Associations of clinical findings and laboratory parameters with accumulating OS

Kaplan-Meier plot curves and univariate Cox's proportional hazard regression were used to investigate the associations of clinical findings and laboratory parameters with accumulating OS and the results suggested that female sex, age less than 28 months (Figure 2A), coma (Figure 2B), convulsions on admission, respiratory failure, multiple organ dysfunction syndrome (MODS) (omit RF), ventilation, septic shock, non-adjuvant steroid therapy (Figure 2C), and higher protein level in CSF were associated with shorter OS in pediatric PM patients (Table 5). Further multivariate Cox's proportional hazard regression revealed that age less than 28 months (aHR=6.479, 95%CI=1.153-36.404, P=0.034), coma (aHR=9.808, 95%CI=2.802-34.323, P=0.000), and non-adjuvant steroid therapy (aHR=4.768 95% CI=1.946-11.678, P=0.001) were independent prognostic factors for poor OS in pediatric PM patients (Table 5).

NoVESNoVESSexMale21230.0610.805Female40486013.2470.00028 months346013.2470.000>28 months27117100.406Duration of disease54 days37480.6910.40624 days24230.5010.4060.406Consciousness stateNormal44422.4880.288Decline in consciousness101610.001Convulsions on admissionNO66670.3390.560YES153500.56070.560YES5680.0810.77671MoDSYES23111290.286Mechanical ventilationNO59680.0810.776YES51011290.2851Adjuvant steroid therapyNO58670.0310.855YES531011920.276Mush steroid therapyNO16180.0130.909YES4553111040.011Mush steroid therapyNO16180.0100.920Mush steroid therapyNO16180.0100.920Mush steroid therapyNO16180.0100.920Mush steroid therapy	Parameters	Subgroups	Complications		Chi-squared	P-value
SexMale21230.0610.805Female4048			NO	YES		
AgeFemale404899Age conths34601.2470.0028 months27180.6910.406Duration of disease4 days2423A days2423Consciousness stateNormal442Consciousness state016Convalors stateNormal713Convalors stateNO4636Convalors stateNO5667Respiratory failureNO5661MCDSS64MCDSNO5661Mechanical ventilationNO5661Mechanical ventilationNO5867Mechanical ventilationNO5867	Sex	Male	21	23	0.061	0.805
Age528 month)34601.2.470.00028 months2711111Duration of disease54 days37480.6910.40624 days2423222Consciousness stateNormal44422.4880.288Delnie in consciousness101610.004Convulsions on admissionNO46368.5110.004PES153510.004MODS56670.3390.560MCDSNO56611.1290.288MCDSNO56611.290.288Mechanical ventilationNO58670.0330.855Sptic shock on admissionNO58670.0330.855Adjuvant steroid therapyNO585310.0130.909YES3410.0130.9010.916MCDSEarly15121.1040.0170.275Mubbicits treatmentEarly15180.0100.916MCSin IDSOHigh15180.0100.916MCSin IDSOHigh15101.1040.917Mubbicits treatmentEarly133511Late463611.1040.9171MCSin IDSOHigh15180.0100.916Mubbicits treatment		Female	40	48		
28 months271110Duration of disease54 days37480.6910.40624 days2423230.2880.288Consciousness stateNormal422.4880.288Decline in consciousness101611Comulsion on admissionComa71311Consultations on admissionNO46368.5110.001Tes1535111MODS56670.3390.560MCDS54111MCDS1631111MCDS1611.1290.288MCDS1611.1290.288MCDS1611.1290.288MCDS16180.0130.855MCT16180.0130.855MCT153311MCT151.1040.0130.999MCT16180.0130.991MCT16180.0130.991MCT16161.1040.011MCT16161.1040.011MCT16161.1040.011MCT16161.1040.011MCT16161.1040.011MCT16161.1040.011MCT16161.104 <t< td=""><td>Age</td><td>≤28 months)</td><td>34</td><td>60</td><td>13.247</td><td>0.000</td></t<>	Age	≤28 months)	34	60	13.247	0.000
Duration of disease54 days37480.6910.406> >4 days2423		>28 months	27	11		
A days2423AdaysAdaysConsciousness stateNormal44422,4880,288Decline in consciousness10161616Coma7131616Convulsions on admissionNO46368,5110.004YES1535717Respiratory failureNO56670,3390,560MODSNO59680,0810,776MCDSNO59680,0810,776Mechanical ventilationNO59611,1290,285YES510111,1290,285Adjuvant steroid therapyNO58670,0330,855YES3411,920,276Artibiotics treatmentEarly15121,1920,276Late4659110,013101VBCs in bloodHigh15180,0100,901Glucose in CSFHigh15180,0100,991Idvinu24280,0000,9911,9120,914Protein in CSFLow26381,5150,218Indig292511,920,2161,912Protein in CSFKigh292511,9120,912Indig292511,9120,9121,912Indig2925<	Duration of disease	≤4 days	37	48	0.691	0.406
Consciousness stateNormal44422.4880.288Decline in consciousness10161616Coma7131310Convulsions on admissionNO46368.5110.004YES1535101010MODSNO56670.3390.560MODSNO59680.0810.776MoDSNO56611.1290.288Mechanical ventilationNO56611.1290.288Septic shock on admissionNO58670.0330.855NO58670.0330.8551010Adjuvant steroid therapyNO16180.0130.909YES34110.215121.1920.275McCs in CSFHigh483611.1040.0010.001Low133511100.0010.921Gucose in CSFHigh24280.0000.991Low3743151550.218Protein in CSFNO28381.5150.218High2925126.3010.218Protein in CSFNO28386.0000.991High2925126.3010.218Concomitant diseaseNO22126.3010.012Mechanical functione		>4 days	24	23		
Decline in consciousness1016Image: section of the sec	Consciousness state	Normal	44	42	2.488	0.288
Coma7131Convulsions on admissionNO46368.5110.004YES5350.33900.560Respiratory failureNO5641MODSNO59680.0810.776YES2311Mechanical ventilationNO56611.1290.288Septic shock on admissionNO58670.0330.855YES341111Adjuvant steroid therapyNO16180.0130.909YES4553110.276MBCS in bloodHigh483611.1040.011UBCS in CSFHigh15180.0100.920Glucose in CSFHigh15180.0000.991Tortein in CSFLow28381.5150.218Protein in CSFNO2231.5150.218High222510.0000.9110.912Protein in CSFLow28381.5150.218High22331.5150.218High22333.510.012Protein in CSFNO28381.5150.218High222533.510.012High222533.510.012High22253.510		Decline in consciousness	10	16		
Convulsions on admissionNO46368.5110.004YES153577Respiratory failureNO56670.3397MODSNO59680.0810.776MODSNO59680.0810.776Mechanical ventilationNO56611.1290.288YES510777Septic shock on admissionNO56611.1290.885YES34777Adjuvant steroid therapyNO16180.0130.909YES4553777Antibiotics treatmentEarly15121.1920.201UBCS in DIoOHigh483611.1040.001Comu1335777Glucose in CSFHigh15180.0100.920Low3743777Protein in CSFLow28381.5150.218High29257777Protein in CSFNG22126.3010.012High2925777Protein in CSFNG38660.3010.012High2925777Protein in CSFNG39396.3010.012High29221		Coma	7	13		
YESIS35Image: section of the section o	Convulsions on admission	NO	46	36	8.511	0.004
Respiratory failureNO56670.3390.560YES54MODSNO59680.08176YES23Mechanical ventilationNO56611.1290.288Septic shock on admissionNO58670.0330.855YES510Adjuvant steroid therapyNO58670.0130.855YES34Atbibotics treatmentEarly151.1920.275Late4659WBCs in bloodHigh48361.1040.001Glucose in CSFHigh15180.0000.991Low3743Protein in CSFLow2225High2925Predisposing factorsNO38460.0300.618YES22126.0010.0120.018YES2225YES225YES225YES22126.0030.863-YES2225YES225YES225<		YES	15	35		
YES54	Respiratory failure	NO	56	67	0.339	0.560
MODSNO59680.0810.776YES23Mechanical ventilationNO56611.1290.288YES510Septic shock on admissionNO58670.0330.855YES34Adjuvant steroid therapyNO16180.0130.909YES3553Antibiotics treatmentEarly15121.1920.275Late4659WBCs in bloodHigh483611.1040.001Low1335Glucose in CSFHigh24280.0000.991Low3743Protein in CSFLow2836.11.5150.18High2925Protein in CSFNO2836.00.012-High2925Predisposing factorsNO2859NO2859YES3959YES2959YES2225YES2225YES2225		YES	5	4		
YES23	MODS	NO	59	68	0.081	0.776
Mechanical ventilationNO56611.1290.288YES5107Septic shock on admissionNO58670.0330.855YES3477Adjuvant steroid therapyNO16180.0130.909YES4553777Antibiotics treatmentEarly15121.1920.275Late4659777WBCs in bloodHigh483611.1040.001Low1335777MBCs in CSFHigh15180.0109.91Low3743717Protein in CSFLow28381.5150.218Indip292577Predisposing factorsNO22126.3010.012YES2225777		YES	2	3		
YES510And Construction58670.0336855Septic shock on admissionNO58670.0330.855Adjuvant steroid therapyNO16180.0130.909YES4553Antibiotics treatmentEarly15121.1920.275Late4659VBCs in bloodHigh483611.1040.001Low1335VBCs in CSFHigh5450Low24280.0000.991Protein in CSFLow28381.5150.218Predisposing factorsNO22126.3010.012YES2225	Mechanical ventilation	NO	56	61	1.129	0.288
Septic shock on admissionNO58670.0330.855YES34Adjuvant steroid therapyNO16180.0130.909YES4553Antibiotics treatmentEarly15121.1920.275Late4659WBCs in bloodHigh483611.1040.001Low1335WBCs in CSFHigh15180.0100.920Low4050Glucose in CSFHigh24280.0000.991Low3743Protein in CSFLow28381.5150.218High2925YES3959YES2225YES2225YES2225YES2225YES2225		YES	5	10		
YES34Adjuvant steroid therapyYES16180.0130.909YES4553	Septic shock on admission	NO	58	67	0.033	0.855
Adjuvant steroid therapy NO 16 18 0.013 0.909 YES 45 53 - <t< td=""><td></td><td>YES</td><td>3</td><td>4</td><td></td><td></td></t<>		YES	3	4		
YES4553Image: state sta	Adjuvant steroid therapy	NO	16	18	0.013	0.909
Antibiotics treatmentEarly15121.1920.275Late4659WBCs in bloodHigh483611.1040.001Low1335WBCs in CSFHigh15180.0100.920Low4050Glucose in CSFHigh24280.0000.991Low3743Protein in CSFLow28381.5150.218High2925Predisposing factorsNO22126.3010.012YES2225		YES	45	53		
Late4659AndAndWBCs in bloodHigh483611.1040.001Low13350.0100.920WBCs in CSFHigh15180.0100.920Glucose in CSFHigh24280.0000.991Low374390.991Protein in CSFLow28381.5150.218Predisposing factorsNO22126.3010.012YES3959999YES22250.0300.863	Antibiotics treatment	Early	15	12	1.192	0.275
WBCs in blood High 48 36 11.104 0.001 Low 13 35 1 0.010 0.920 WBCs in CSF High 15 18 0.010 0.920 Glucose in CSF High 24 28 0.000 0.991 Low 37 43 1 1 1 1 Protein in CSF Low 28 38 1.515 0.218 High 29 25 1 1 1 1 Predisposing factors NO 22 12 6.301 0.012 YES 38 46 0.030 0.863 1		Late	46	59		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	WBCs in blood	High	48	36	11.104	0.001
WBCs in CSF High 15 18 0.010 0.920 Low 40 50 1		Low	13	35		
Low4050AndAndGlucose in CSFHigh24280.0000.991Low37437437Protein in CSFLow28381.5150.218High29257710Predisposing factorsNO22126.3010.012YES3959999YES2225100.863	WBCs in CSF	High	15	18	0.010	0.920
Glucose in CSF High 24 28 0.000 0.991 Low 37 43 - <t< td=""><td></td><td>Low</td><td>40</td><td>50</td><td></td><td></td></t<>		Low	40	50		
Low 37 43 And	Glucose in CSF	High	24	28	0.000	0.991
Protein in CSF Low 28 38 1.515 0.218 High 29 25 1 <t< td=""><td></td><td>Low</td><td>37</td><td>43</td><td></td><td></td></t<>		Low	37	43		
High 29 25 Andress Andreandendendeddeddeddeddeddeddeddeddeddedded	Protein in CSF	Low	28	38	1.515	0.218
Predisposing factors NO 22 12 6.301 0.012 YES 39 59 -		High	29	25		
YES 39 59 46 0.030 0.863 YES 22 25 25 25 26 27 25	Predisposing factors	NO	22	12	6.301	0.012
Concomitant disease NO 38 46 0.030 0.863 YES 22 25 25 1 1		YES	39	59		
YES 22 25	Concomitant disease	NO	38	46	0.030	0.863
		YES	22	25		

Table 3 Associations of the clinical features with complications in pediatric PM patients analyzed by chi-squared test

Note: Bold, indicates P<0.05.

Abbreviations: PM, pneumococcal meningitis; MODS, multiple organ dysfunction syndrome; CSF, cerebrospinal fluid; WBC, white blood cell.

Table 4 Associations of the clinical features with complications inpediatric PM patients analyzed by multivariate logistic regression

Parameters	P-value	OR	95%C	I
Age (≤28 months vs >28 months)	0.036	2.654	1.067	6.600
Convulsions on admission (YES vs NO)	0.156	1.823	0.795	4.181
WBCs in blood (low vs high)	0.006	3.169	1.395	7.202
Predisposing factors (YES vs	0.150	1.946	0.785	4.825

Note: Bold, indicates P<0.05.

Abbreviations: PM, pneumococcal meningitis; WBC, white blood cell.

Correlation of clinical findings and laboratory parameters with accumulating SFS

Associations of clinical findings and laboratory parameters with accumulating SFS were also explored. The Kaplan-Meier curves and univariate Cox's proportional hazard regression suggested that coma (Figure 3A), convulsions on admission, respiratory failure, MODS (omit RF), mechanical ventilation, septic shock on admission (Figure 3B), non-adjuvant steroid therapy,



Figure 2 Associations of clinical characteristics with accumulating overall survival in pediatric pneumococcal meningitis (PM) patients were analyzed by Kaplan-Meier plot curves and logrank test. (A) age; (B) consciousness; (C) steroid therapy.

and lower glucose level in CSF (Figure 3C) were associated with shorter SFS (Table 6). After adjusting the confounding factors, coma (aHR=5.841, 95% CI=2.652–12.864, P=0.000), septic shock on admission (aHR=2.949, 95%CI=1.049–8.290, P=0.040), and lower glucose level in CSF (aHR=2.523, 95%CI=1.336–4.765, P=0.004) were found to be independent prognostic factors for unfavorable SFS in multivariate analyses (Table 6).

Discussion

In the present multicenter study, we included 132 pediatric patients and revealed that the overall mortality of these patients was 18.9% and the rate of focal neurological sequelae 36.4%, which were higher than that observed in US or European populations.^{5–8,17,25,27,28} A meta-analysis in 1993, including mainly US and European cohorts, revealed a mortality rate of 4.8%–8.1% and a neurological handicap rate of 16%–26% in pediatric PM patients.²⁹ Another meta-analysis in 2014, performed in Latin American and Caribbean populations, suggested that the mortality rate of pediatric PM patents was 8.3%.³⁰ In developing countries and regions such as sub-Saharan Africa, the mortality of PM patients has been reported to be as high as 73%.^{7,9–13} The mortality of pediatric PM patients in China was higher than US or European cohorts but lower than African cohorts. The higher mortality and neurological sequelae rates emphasized the need to identify early prognostic factors for pediatric PM patients.

Of the 132 pediatric PM patients in the study, meningitis-associated intracranial complications were found in

Parameters	Univariate analysis			Multivariate analysis				
	P-value	HR	95%CI		P-value	HR	95%CI	
Sex (female vs male)	0.010	2.812	1.276	6.199	0.189	1.774	0.754	4.171
Age (≤28 months vs >28 months)	0.028	5.032	1.186	21.346	0.034	6.479	1.153	36.404
Duration of disease (>4 days vs ≤4 days)	0.189	1.692	0.772	3.709				
Complications (YES vs NO)	0.473	0.750	0.342	1.645				
Consciousness state	0.000				0.002			
Normal		Ref				Ref.		
Decline in consciousness	0.202	2.071	0.678	6.332	0.079	2.916	0.882	9.643
Coma	0.000	10.641	4.321	26.201	0.000	9.808	2.802	34.323
Convulsions on admission (YES vs NO)	0.043	2.258	1.025	4.976	0.205	0.442	0.125	1.560
Respiratory failure (YES vs NO)	0.000	8.988	3.705	21.806	0.396	1.903	0.431	8.401
MODS (YES vs NO)	0.001	6.363	2.170	18.659	0.326	1.808	0.555	5.888
Mechanical ventilation (YES vs NO)	0.000	5.781	2.547	13.124	0.194	2.572	0.619	10.683
Septic shock on admission (YES vs NO)	0.000	14.465	5.519	37.914	0.053	3.927	0.983	15.693
Adjuvant steroid therapy (NO vs YES)	0.000	4.491	2.036	9.906	0.001	4.768	1.946	11.678
Antibiotics treatment (late vs early)	0.531	1.408	0.483	4.102				
WBCs in blood (low vs high)	0.174	1.723	0.786	3.776				
WBCs in CSF (low vs high)	0.144	2.054	0.782	5.399				
Glucose in CSF (low vs high)	0.147	1.990	0.785	5.049				
Protein in CSF (high vs low)	0.034	2.536	1.074	5.984	0.953	1.039	0.292	3.693
Concomitant disease (YES vs NO)	0.065	2.512	0.943	6.696				
Predisposing factors (YES vs NO)	0.780	0.883	0.369	2.114				

 Table 5 Associations of the clinical features with accumulating OS in pediatric PM patients analyzed by Cox's proportional hazard regression

Note: Bold, indicates P<0.05.

Abbreviations: OS, overall survivalPM, pneumococcal meningitis; MODS, multiple organ dysfunction syndrome; CSF, cerebrospinal fluid; WBC, white blood cell.

53.8% patients by cranial CT or MRI. The most common intracranial complications were subdural effusion, cerebritis, cerebral edema, and hydrocephalus. The prevalence of cerebritis and hydrocephalus in our study was higher than adult PM patients in previous study of.³¹ The prevalence of concomitant diseases was 63.6% in our study and was similar to the results of previous reports.^{31–34}

After multivariate analyses of the prognostic factors in predicting complications, OS, and SFS outcomes in pediatric PM patients, we identified that age less than months was associated with complications 28 (aOR=2.654, 95%CI=1.067-6.600, P=0.036) and short OS (aHR=6.479, 95%CI=1.153-36.404, P=0.034), coma on admission was associated with short OS (aHR=9.808, 95%CI=2.802-34.323, P=0.000) and SFS (aHR=5.841, 95%CI=2.652-12.864, P=0.000), non-adjuvant steroid therapy was associated with short OS (aHR=4.768 95%CI=1.946-11.678, P=0.001), and septic shock on admission was associated with poor SFS (aHR=2.949, 95%CI=1.049-8.290, P=0.040). Our results were similar to previous reports.^{16,17,25,26} According to previous evidence, the CSF of PM patients usually shows aberrant WBC count, protein level, and glucose level, thus we also analyzed the prognostic value of WBCs in blood or CSF, protein in CSF, and glucose in CSF to predict complications, OS, and SFS in pediatric PM patients. Our result suggested that lower WBCs in blood was an independent predictive factor of complications and lower glucose level in CSF was an independent prognostic factor of poor SFS. Leukopenia is reflective of severe sepsis, and lower peripheral blood and CSF WBC counts may indicate inadequacy of the immune response. Chao et al also found an association between lower WBCs in CSF and higher mortality in PM.¹⁹ Lower glucose levels in the CSF is correlated with increased inflammation and cytokine levels³⁵ and the inflammatory response is implicated in the pathogenesis of PM and associated brain injury and neuronal death, via releasing potentially cytotoxic agents such as ROS and proteolytic enzymes by leucocytes recruited during the inflammatory response.³⁶ A lower glucose level in CSF can indicate increased central nervous system inflammation, which is expected to result in a higher risk of neurological sequelae and poor SFS in PM



Figure 3 Associations of clinical characteristics and laboratory parameters with accumulating sequelae-free survival in pediatric pneumococcal meningitis (PM) patients were analyzed by Kaplan-Meier plot curves and logrank test. (A) Consciousness; (B) septic shock; (C) glucose in cerebrospinal fluid (CSF).

patients. High protein levels in CSF are related to more severe inflammatory reactions and immune responses during bacterial meningitis,^{37,38} and may also be a predictor of later poor outcomes in PM patients, although we only observed an association between protein level in CSF and OS in univariate analysis.

This study is the most comprehensive nationwide, multi-centric study on pediatric PM in mainland China up to date. However, some limitations still existed in our study. Firstly, information on capsular serotyping of the pediatric PM patients in our retrospective study was not available and the associations of serotype distribution with clinical outcomes of the patients were not clear. Secondly, although pneumococcal vaccines have been licensed in mainland China, none of the patients in our study received pneumococcal vaccination, which might also be associated with prognosis in PM patients.

Conclusion

Our study showed that PM is a disease with high mortality and neurological sequelae in pediatric patients, and complications during the clinical course occur frequently. In pediatric PM patients, age less than 28 months and lower WBCs in blood were independent predictive factors for complications; age less than 28 months, coma, and non-adjuvant steroid therapy were independent prognostic factors for poor OS; and coma, septic shock on admission, and lower glucose level in CSF were independent prognostic factors for poor SFS.

Parameters	Univariate analysis			Multivariate analysis				
	P-value	HR	95%CI		P-value	HR	95%CI	
Sex (female vs male)	0.521	1.184	0.706	1.985				
Age (≤28 months vs >28 months)	0.181	1.485	0.832	2.650				
Duration of disease (>4 days vs ≤4 days)	0.064	1.593	0.973	2.609				
Complications (YES vs NO)	0.457	1.208	0.735	1.984				
Consciousness state Normal Decline in consciousness Coma	0.000 0.079 0.000	Ref 1.735 4.971	0.939 2.732	3.207 9.046	0.000 0.080 0.000	Ref 1.789 5.841	0.932 2.652	3.434 12.864
Convulsions on admission (YES vs NO)	0.050	1.638	1.001	2.683	0.915	1.034	0.559	1.912
Respiratory failure (YES vs NO)	0.000	4.337	2.037	9.233	0.566	1.413	0.433	4.607
MODS (YES vs NO)	0.003	4.041	1.591	10.260	0.209	1.868	0.704	4.954
Mechanical ventilation (YES vs NO)	0.008	2.404	1.252	4.618	0.783	1.148	0.430	3.060
Septic shock on admission (YES vs NO)	0.000	5.446	2.307	12.858	0.040	2.949	1.049	8.290
Adjuvant steroid therapy (NO vs YES)	0.030	1.785	1.058	3.011	0.055	1.771	0.989	3.173
Antibiotics treatment (late vs early)	0.425	0.794	0.450	1.399				
WBCs in blood (low vs high)	0.059	1.610	0.982	2.641				
WBCs in CSF (low vs high)	0.062	1.695	0.974	2.950				
Glucose in CSF (low vs high)	0.004	2.345	1.304	4.217	0.004	2.523	1.336	4.765
Protein in CSF (high vs low)	0.318	1.301	0.777	2.178				
Concomitant disease (YES vs NO)	0.848	1.051	0.633	1.744				
Predisposing factors (YES vs NO)	0.990	0.997	0.566	1.755				

Table 6 Associations of the clinical features with accumulatin	ating SFS analyzed by Cox's proportional hazard regressi
--	--

Note: Bold, indicates P<0.05.

Abbreviations: SFS, sequelae-free survival; PM, pneumococcal meningitis; MODS, multiple organ dysfunction syndrome; CSF, cerebrospinal fluid; WBC, white blood cell.

Ethics

The present study was approved by the Ethics Committee of the Children's Hospital of Zhejiang University School of Medicine. Each PM patient was anonymous in the study and patient/parental consent requirement was waived due to the anonymized data.

Acknowledgments

We would like to thank Aiwei Lin (Qilu Children's Hospital of Shandong University), Qing Cao (Shanghai Children's Medical Center of Shanghai Jiaotong University School of Medicine), and Ting Zhang (Children's Hospital of Shanghai Jiaotong University School of Medicine) for re-analyzing the data when revising our manuscript after peer review.

Author contributions

Caiyun Wang, Hongmei Xu, Jikui Deng, Hui Yu, Yiping Chen, Shifu Wang, Weichun Huang, Jianhua Hao, Chun Wang, Huiling Deng, and Yinghu Chen designed the study. Caiyun Wang and Yinghu Chen drafted the manuscript. All authors contributed to data analysis, drafting and revising the article. All authors gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

- Nuoh RD, Nyarko KM, Nortey P, et al. Review of meningitis surveillance data, upper West Region, Ghana 2009-2013. *Pan Afr Med J*. 2016;25(Suppl 1):9.
- Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med. 2011;364 (21):2016–2025. doi:10.1056/NEJMoa1007994
- Xie Y, Tan Y, Chongsuvivatwong V, et al. A population-based acute meningitis and encephalitis syndromes surveillance in Guangxi, China, May 2007-June 2012. *PLoS One.* 2015;10(12):e0144366. doi:10.1371/journal.pone.0144366
- Davis LE. Acute bacterial meningitis. *Continuum (Minneap Minn)*. 2018;24(5, Neuroinfectious Disease):1264–1283.
- Buchholz G, Koedel U, Pfister HW, Kastenbauer S, Klein M. Dramatic reduction of mortality in pneumococcal meningitis. *Crit Care*. 2016;20(1):312. doi:10.1186/s13054-016-1362-x
- Bijlsma MW, Brouwer MC, Kasanmoentalib ES, et al. Communityacquired bacterial meningitis in adults in the Netherlands, 2006-14: a prospective cohort study. *Lancet Infect Dis.* 2016;16(3):339–347. doi:10.1016/S1473-3099(16)30197-9
- McGill F, Heyderman RS, Panagiotou S, Tunkel AR, Solomon T. Acute bacterial meningitis in adults. *Lancet*. 2016;388 (10063):3036–3047. doi:10.1016/S0140-6736(16)30654-7
- Hasbun R, Rosenthal N, Balada-Llasat JM, et al. Epidemiology of meningitis and encephalitis in the United States, 2011-2014. *Clin Infect Dis.* 2017;65(3):359–363. doi:10.1093/cid/cix474
- Stockmann C, Ampofo K, Byington CL, et al. Pneumococcal meningitis in children: epidemiology, serotypes, and outcomes from 1997-2010 in Utah. *Pediatrics*. 2013;132(3):421–428. doi:10.1542/ peds.2013-0621
- O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. *Lancet*. 2009;374(9693):893–902. doi:10.1016/S0140-6736(09)61069-2
- Gil Prieto R, San Roman Montero J, Gomez Alejandre C, Alvaro Meca LA, Rivero A, Gil de Miguel A. Epidemiology of pneumococcal meningitis hospitalizations in pediatric population in Spain (1998–2006). *Vaccine*. 2009;27(20):2669–2673.
- Levy C, Varon E, Picard C, et al. Trends of pneumococcal meningitis in children after introduction of the 13-valent pneumococcal conjugate vaccine in France. *Pediatr Infect Dis J.* 2014;33(12):1216–1221. doi:10.1097/INF.000000000000309
- Mortality GBD, Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet*. 2015;385(9963):117–171. doi:10.1016/ S0140-6736(14)61682-2
- Lucas MJ, Brouwer MC, van de Beek D. Neurological sequelae of bacterial meningitis. J Infect. 2016;73(1):18–27. doi:10.1016/j. jinf.2016.04.009
- Dorsett M, Liang SY. Diagnosis and treatment of central nervous system infections in the emergency department. *Emerg Med Clin North Am.* 2016;34(4):917–942. doi:10.1016/j.emc.2016.06.013
- Erdem H, Elaldi N, Oztoprak N, et al. Mortality indicators in pneumococcal meningitis: therapeutic implications. *Int J Infect Dis.* 2014;19:13–19. doi:10.1016/j.ijid.2013.09.012

- Jordan I, Calzada Y, Monfort L, et al. Clinical, biochemical and microbiological factors associated with the prognosis of pneumococcal meningitis in children. *Enferm Infecc Microbiol Clin.* 2016;34 (2):101–107. doi:10.1016/j.eimc.2015.03.004
- Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. *Cochrane Database Syst Rev.* 2015;(9): CD004405.
- Chao YN, Chiu NC, Huang FY. Clinical features and prognostic factors in childhood pneumococcal meningitis. J Microbiol Immunol Infect. 2008;41(1):48–53.
- Pagliano P, Fusco U, Attanasio V, et al. Pneumococcal meningitis in childhood: a longitudinal prospective study. *FEMS Immunol Med Microbiol.* 2007;51(3):488–495. doi:10.1111/j.1574-695X.2007.00324.x
- 21. Irene Koomen DE, Grobbee JJ, Roord RD, Jennekens-Schinkel A, Van Furth AM. Hearing loss at school age in survivors of bacterial meningitis_assessment, incidence, and prediction. *Pediatrics*. 2003;112(5):1049–1053. doi:10.1542/peds.112.5.1049
- 22. McIntyre PB, Macintyre CR, Gilmour R, Wang H. A population based study of the impact of corticosteroid therapy and delayed diagnosis on the outcome of childhood pneumococcal meningitis. *Arch Dis Child.* 2005;90(4):391–396. doi:10.1136/adc.2004.05 5335
- Kaplan SL, Goddard J, Van Kleeck M, Catlin FI, Rd. F. Ataxia and deafness in children due to bacterial meningitis. *Pediatrics*. 1981;68 (1):8–13.
- Weisfelt M, Hoogman M, van de Beek D, de Gans J, Dreschler WA, Schmand BA. Dexamethasone and long-term outcome in adults with bacterial meningitis. *Ann Neurol.* 2006;60(4):456–468. doi:10.1002/ ana.20944
- 25. Kornelisse RF, Westerbeek CML, Spoor AB, et al. Pneumococcal meningitis in children: prognostic indicators and outcome. *Clin Infect Dis.* 1995;21(6):1390–1397. doi:10.1093/clinids/21.6.1 390
- 26. Selva L, Ciruela P, Esteva C, et al. Serotype 3 is a common serotype causing invasive pneumococcal disease in children less than 5 years old, as identified by real-time PCR. *Eur J Clin Microbiol Infect Dis.* 2012;31(7):1487–1495. doi:10.1007/ s10096-011-1468-7
- Arditi M, Mason EO, Bradley JS, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. *Pediatrics*. 1998;102(5):1087–1097.
- Buckingham SC, McCullers JA, Luján-Zilbermann J, Knapp KM, Orman KL, English BK. Early vancomycin therapy and adverse outcomes in children with pneumococcal meningitis. *Pediatrics*. 2006;117(5):1688–1694. doi:10.1542/peds.2005-2282
- Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. *Pediatr Infect Dis J.* 1993;12(5):389–394. doi:10.1097/00006454-199305000-00008
- Ciapponi A, Elorriaga N, Rojas JI, et al. Epidemiology of pediatric pneumococcal meningitis and bacteremia in Latin America and the caribbean: a systematic review and meta-analysis. *Pediatr Infect Dis J.* 2014;33(9):971–978. doi:10.1097/ INF.0000000000000309
- 31. Weisfelt M, van de Beek D, Spanjaard L, Reitsma JB, de Gans J. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. *Lancet Neurol.* 2006;5(2):123–129. doi:10.1016/S1474-4422(05)70288-X
- Hoen B, Viel JF, Gérard A, Dureux JB, Canton P. Mortality in pneumococcal meningitis: a multivariate analysis of prognostic factors. *Eur J Med.* 1993;2(1):28–32.
- 33. Auburtin M, Porcher R, Bruneel F, et al. Pneumococcal meningitis in the intensive care unit prognostic factors of clinicaloutcome in a series of 80 cases. *Am J Respir Crit Care Med.* 2002;165 (5):713–717. doi:10.1164/ajrccm.165.8.2106104

- 34. Kastenbauer S, Pfister HW. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. *Brain*. 2003;126(5):1015–1025. doi:10.1093/brain/awg113
- Low PS, Lee BW, Yap HK, et al. Inflammatory response in bacterial meningitis: cytokine levels in the cerebrospinal fluid. *Ann Trop Paediatr.* 1995;15(1):55–59.
- Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D. Pathogenesis and pathophysiology of pneumococcal meningitis. *Clin Microbiol Rev.* 2011;24(3):557–591.
- 37. Kim KS. Acute bacterial meningitis in infants and children. Lancet Infect Dis. 2010;10(1):32–42. doi:10.1016/S1473-3099(09)70306-8
- Barichello T, Fagundes GD, Generoso JS, Elias SG, Simoes LR, Teixeira AL. Pathophysiology of neonatal acute bacterial meningitis. J Med Microbiol. 2013;62(Pt 12):1781–1789. doi:10. 1099/jmm.0.059840-0

Infection and Drug Resistance

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed openaccess journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

Submit your manuscript here: https://www.dovepress.com/infection-and-drug-resistance-journal

Dovepress

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peerreview system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors.